Webform

Webform

ZERO Summit 2021 banner

Understanding Today's Treatment Challenges

Two representatives of Erleada at a tabling event

Erleada, also known as apalutamide, is an androgen receptor inhibitor that was approved by the FDA for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Chelsie Ferrell, a physician assistant at Advanced Urology Institute, talks about Erleada as a prostate cancer treatment option, as well as its possible side effects and how to manage them.

This session was part of our VIRTUAL ZERO Prostate Cancer Summit, a free online event that took place from February 28 to March 4, 2021.


Watch

Contributor

Shelby Moneer Headshot
Shelby Moneer, Vice President, Patient Programs & Education

Shelby Moneer was the Vice President of Patient Programs & Education at ZERO Prostate Cancer until April 2025.

Share